Rituximab for the treatment of rheumatoid arthritis

Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A
Record ID 32006001092
Authors' objectives:

The purpose of this report is to assess the efficacy of rituximab in the treatment of rheumatoid arthritis and to determine validated indications for its use.

Authors' recommendations: Based on the published data, rituximab, used in combination with methotrexate (MTX) or cyclophosphamide, has shown benefits in rheumatoic arthritis (RA) treatment which is refractory to other drugs. However, additional controlled trials are needed to determine optimal dose, response rates and long term effectiveness, as well as the position of rituximab in the management algorithm of RA in this patient population, since there are no studies comparing rituximab to other treatment options other than MTX. Special attention must be paid to the surveillance of serious infections. It is a drug that represents a potentially expensive cost for health systems. That is why, in the countries where it is covered, its use is reserved for those selected subgroups of patients with active RA who have not adequately responded to conventional treatment with MTX and biological agents or who have not tolerated them.
Authors' methods: Overview
Project Status: Completed
URL for project: http://www.iecs.org.ar/
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Methotrexate
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.